drugset / Trial / NCT01031810
PET Biomarkers in Treatment Resistant Depression
Phase 4
Terminated
13 enrolled
New York State Psychiatric Institute
National Institute of Mental Health (NIMH) · collab
NaSingle-groupOpen-labelTreatment
Summary
The primary objectives of the study are to test whether brain Mono Amine Oxidase-A (MAO-A) levels are elevated in patients with treatment-resistant major depression, and to explore whether MAO-A brain levels predict treatment outcome with Mono Amine Oxidase Inhibitor (MAOI) medication in this population.
Timeline
- Start
- 2009-11
- Primary completion
- 2013-03
- Completion
- 2013-03
Outcome
Outcome not reported
Stopped: “Needed PET facility closed”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tranylcypromine | Small molecule | 60 mg | — |
| Subject | Tranylcypromine | Small molecule | 120 mg | — |